DC6001 Tablet Study in Healthy Chinese Adults
Part of Eyes & vision, Genetic & congenital clinical trials.
This trial tests a new tablet called DC6001 in healthy volunteers. It helps find out how the body processes the drug and if it is safe. You may join if you are a healthy adult between 18 and 55 years old.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 to 55 years old, healthy, and willing to use birth control.
- Men must weigh at least 110 pounds (50 kg), and women at least 99 pounds (45 kg).
- Your body mass index (BMI) must be between 19 and 28.
- You must not smoke more than 5 cigarettes a day on average, and cannot smoke during the study.
- You must not have taken any other experimental drugs in the last 3 months.
- You must not have donated blood (400 mL or more) in the last 3 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, ALK-001, to see if it can slow down vision loss from Stargardt disease. It is for people who have a confirmed genetic diagnosis and are between 8 and 45 years old.
This trial tests a new gene therapy called SB-007 for people with Stargardt disease (STGD1). It is given as an injection under the retina to see if it is safe and can help slow vision loss.
This study follows people with Stargardt disease (a genetic eye condition that causes vision loss) over time. It aims to learn more about how the disease progresses and does not test any treatment.
This trial tests a single injection of a new medicine, RTx-021, into the eye for people with Stargardt disease. The goal is to see if it is safe and to find the right dose.
This trial tests a new tablet drug in healthy people to see how safe it is and how the body processes it. It is an early-stage study, meaning it helps find the right dose and check for side effects.
This study tests a new drug called CITY-RBP4 in healthy volunteers and in people with Stargardt disease (STGD1), a genetic condition that causes vision loss. The goal is to see if the drug is safe and how it affects the body, which may help guide future treatments for Stargardt disease.
Hear when a new Stargardt Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.